Mersana Therapeutics (MRSN) Competitors $9.88 -0.65 (-6.17%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$9.95 +0.07 (+0.71%) As of 10/17/2025 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRSN vs. ACTU, CCCC, PYXS, CTOR, THTX, ACOG, NVCT, NKTX, MOLN, and GLSIShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Actuate Therapeutics (ACTU), C4 Therapeutics (CCCC), Pyxis Oncology (PYXS), Citius Oncology (CTOR), Theratechnologies (THTX), Alpha Cognition (ACOG), Nuvectis Pharma (NVCT), Nkarta (NKTX), Molecular Partners (MOLN), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. Its Competitors Actuate Therapeutics C4 Therapeutics Pyxis Oncology Citius Oncology Theratechnologies Alpha Cognition Nuvectis Pharma Nkarta Molecular Partners Greenwich LifeSciences Actuate Therapeutics (NASDAQ:ACTU) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment. Do analysts rate ACTU or MRSN? Actuate Therapeutics currently has a consensus price target of $20.33, indicating a potential upside of 171.84%. Mersana Therapeutics has a consensus price target of $56.60, indicating a potential upside of 472.87%. Given Mersana Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mersana Therapeutics is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Mersana Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media refer more to ACTU or MRSN? In the previous week, Actuate Therapeutics' average media sentiment score of 0.00 equaled Mersana Therapeutics'average media sentiment score. Company Overall Sentiment Actuate Therapeutics Neutral Mersana Therapeutics Neutral Which has more volatility and risk, ACTU or MRSN? Actuate Therapeutics has a beta of -0.23, suggesting that its share price is 123% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Which has preferable earnings & valuation, ACTU or MRSN? Actuate Therapeutics has higher earnings, but lower revenue than Mersana Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/AMersana Therapeutics$34.77M1.42-$69.19M-$14.62-0.68 Is ACTU or MRSN more profitable? Actuate Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A -281.83% Mersana Therapeutics -212.94%N/A -54.85% Do insiders & institutionals have more ownership in ACTU or MRSN? 93.9% of Mersana Therapeutics shares are owned by institutional investors. 69.3% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 13.0% of Mersana Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryMersana Therapeutics beats Actuate Therapeutics on 7 of the 10 factors compared between the two stocks. Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.31M$3.44B$6.19B$10.56BDividend YieldN/A2.27%5.70%4.81%P/E Ratio-0.6823.0185.5427.12Price / Sales1.42500.54613.32133.32Price / CashN/A46.9237.1060.81Price / Book-5.1510.4112.236.52Net Income-$69.19M-$52.77M$3.33B$276.93M7 Day Performance6.93%2.31%1.17%1.93%1 Month Performance36.28%12.59%6.85%2.19%1 Year Performance-81.18%11.18%58.93%34.62% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics4.1034 of 5 stars$9.88-6.2%$56.60+472.9%-81.2%$49.31M$34.77M-0.68150ACTUActuate Therapeutics1.4469 of 5 stars$7.02+0.6%$20.33+189.6%+3.0%$162.24MN/A0.0010CCCCC4 Therapeutics3.5467 of 5 stars$2.28+0.4%$8.50+272.8%-62.7%$161.56M$35.58M-1.44150News CoveragePYXSPyxis Oncology2.8256 of 5 stars$2.47-3.9%$7.75+213.8%-10.4%$159.39M$16.15M-1.5460Gap UpCTORCitius Oncology2.0474 of 5 stars$1.87-1.1%$6.00+220.9%+37.1%$157.84MN/A0.00N/ANews CoverageGap UpTHTXTheratechnologiesN/A$3.42+0.9%N/A+157.1%$157.21M$84.38M-17.99140High Trading VolumeACOGAlpha Cognition2.319 of 5 stars$7.40-1.1%$20.00+170.3%N/A$156.35MN/A-4.63N/AAnalyst DowngradeShort Interest ↑NVCTNuvectis Pharma2.5841 of 5 stars$6.05+0.7%$15.33+153.4%-18.8%$152.87MN/A-5.178News CoverageNKTXNkarta2.4429 of 5 stars$2.15+0.9%$13.60+532.6%-46.0%$151.28MN/A-1.45140High Trading VolumeMOLNMolecular Partners1.4854 of 5 stars$3.72+0.3%$8.00+115.0%-22.1%$149.79M$5.65M-1.79180Analyst ForecastGap DownGLSIGreenwich LifeSciences1.2141 of 5 stars$11.28+3.4%$42.00+272.3%-29.9%$148.71MN/A-8.293Analyst Forecast Related Companies and Tools Related Companies ACTU Competitors CCCC Competitors PYXS Competitors CTOR Competitors THTX Competitors ACOG Competitors NVCT Competitors NKTX Competitors MOLN Competitors GLSI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRSN) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
